Literature DB >> 8957680

Cellular and molecular aspects of monoamine neurotransmitter transporters.

S Kitayama1, T Dohi.   

Abstract

Neurotransmitter transporters terminate synaptic neurotransmission by accumulating neurotransmitters once again after release in a sodium- and chloride-dependent fashion. The availability of the cloned neurotransmitter transporters has allowed investigation into the roles of these transporters in neuronal function. Molecular biological and protein engineering studies including in vitro site-directed mutagenesis, chimera formation of several transporter clones, or epitope-tagging various regions of transporter proteins, have revealed the topology and functionally mapped the transporter proteins. Monoamine neurotransmitter transporters such as those for dopamine, norepinephrine and serotonin are of interest, since they are a target of drugs of abuse and are involved in neuronal disorders including Parkinson's disease and depression. Therefore, elucidating the molecular basis of these transporters may clarify these problems and help develop treatments with which to combat these disorders and drug abuse.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957680     DOI: 10.1254/jjp.72.195

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  7 in total

1.  Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptake.

Authors:  M Syringas; F Janin; B Giros; J Costentin; J J Bonnet
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

2.  Synthesis, in vitro binding studies and docking of long-chain arylpiperazine nitroquipazine analogues, as potential serotonin transporter inhibitors.

Authors:  Małgorzata Jarończyk; Karol Wołosewicz; Mari Gabrielsen; Gabriel Nowak; Irina Kufareva; Aleksander P Mazurek; Aina W Ravna; Ruben Abagyan; Andrzej J Bojarski; Ingebrigt Sylte; Zdzisław Chilmonczyk
Journal:  Eur J Med Chem       Date:  2012-01-15       Impact factor: 6.514

3.  C-terminal region regulates the functional expression of human noradrenaline transporter splice variants.

Authors:  Chiharu Sogawa; Kei Kumagai; Norio Sogawa; Katsuya Morita; Toshihiro Dohi; Shigeo Kitayama
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

4.  Expression and function of variants of human catecholamine transporters lacking the fifth transmembrane region encoded by exon 6.

Authors:  Chiharu Sogawa; Chieko Mitsuhata; Kei Kumagai-Morioka; Norio Sogawa; Kazumi Ohyama; Katsuya Morita; Katsuyuki Kozai; Toshihiro Dohi; Shigeo Kitayama
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

Review 5.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20

6.  Open-label pilot study of modafinil for methamphetamine dependence.

Authors:  Janette McGaugh; Michael J Mancino; Zachary Feldman; Mohit P Chopra; W Brooks Gentry; Christopher Cargile; Alison Oliveto
Journal:  J Clin Psychopharmacol       Date:  2009-10       Impact factor: 3.153

7.  MPP+-Induced Changes in Cellular Impedance as a Measure for Organic Cation Transporter (SLC22A1-3) Activity and Inhibition.

Authors:  Tamara A M Mocking; Hubert J Sijben; Yimé W Vermeulen; Adriaan P IJzerman; Laura H Heitman
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.